

2.3	Centre Update	<p>HR Update:</p> <ul style="list-style-type: none"> The Project Support Officer position has been advertised. 30 applications received so far. Interviews take place next week 26th May. CAS Nurse (advertised via EOI) has been sent out. Closes Wednesday 24th. 2 x Senior Research Office (PO4) positions PMRs with Exec for sign off. Ideal to get 1, but if 2 great applicants – we may employ 2. <p>Finance Update:</p> <ul style="list-style-type: none"> Olivia Ryan in the process of splitting money. \$800,000 to stay in Medicine and \$1.2 million to move into a CHQ research cost centre. An additional cost centre exists under the centre for some external research grants. Honey is manager of this. Completely separate. Some spending is underway. SPSS licence is approx. \$13,000 a year. Quotes requested. <p>Organisational & Centre Structure:</p> <ul style="list-style-type: none"> Org structure – Using the term of Director is where we can get into trouble. Need to take a more clinical approach – a “Clinical Lead”. Next step would be a “Director” with a vision, direction. First steps are to get a centre established with people and banners etc. <ul style="list-style-type: none"> Liaise with Media and Comms to develop the logos, banner and advertise the centre (social media etc.) Host an event to open the centre. Collaborators <ul style="list-style-type: none"> Water young adult’s service? Potentially for studies into Angelman Syndrome. Could be some Governance issues with their being multiple clinicians looking after the participants. Other option is to include them as a site. <p>Next steps:</p> <ul style="list-style-type: none"> Meeting with consultants in Neurology, Development and Metabolic to discuss potential projects they’d like to get on board and how we can help.
3	New Business/Ongoing Actions	
3.1		
4	Action List	
4.1	MC to organise meeting with consultants – Neuro, Development, Metabolics	
5	For information	
5.1		
Meeting concluded at 4:55pm		
Next Meeting: 4pm Wednesday, 14 June 2017, Level 6 Boardroom, CCHR		

From: [Gregory Perry](mailto:Gregory.Perry@health.qld.gov.au)
To: [Tanya Bain](mailto:Tanya.Bain@health.qld.gov.au)
Subject: Fwd: Call for Agenda Items - Neurodevelopmental Disorders Steering Committee - 17th May 2017
Date: Wednesday, 10 May 2017 11:19:29 AM

Sent from my iPhone

Begin forwarded message:

From: Emily Milburn <Emily.Milburn@health.qld.gov.au>
Date: 10 May 2017 at 11:05:06 am AEST
To: Geoff Wallace <Geoff.Wallace@health.qld.gov.au>, Robyn Littlewood <Robyn.Littlewood@health.qld.gov.au>, Gregory Perry <Gregory.Perry@health.qld.gov.au>, Honey Heussler <H.Heussler@health.qld.gov.au>, Melissa Fox <Melissa.Fox@hcq.org.au>, Andrew Hallahan <Andrew.Hallahan@health.qld.gov.au>, CHO_EDMS <CHO_EDMS@health.qld.gov.au>, Rochelle Green <Rochelle.Green@health.qld.gov.au>, Helen Irving <Helen.Irving@health.qld.gov.au>, Sonya Stacey <Sonya.Stacey@health.qld.gov.au>, Michael Carroll <Michael.Carroll@health.qld.gov.au>, Stephen Greene <Stephen.Greene@health.qld.gov.au>
Subject: Re: Call for Agenda Items - Neurodevelopmental Disorders Steering Committee - 17th May 2017

Good Morning All,

If anyone has any agenda items for our meeting next week, could you please forward them through by COB Friday 12th May.

Reminder that we are back in the boardroom next week –

4pm, Wednesday 17th May 2017
Level 6 Boardroom
Centre for Children's Health Research
62 Graham Street, South Brisbane

Kind regards

Emily

Emily Milburn
Project Support Officer (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service
Level 6 – Centre for Children's Health Research
Lady Cilento Children's Hospital Precinct
62 Graham Street, South Brisbane QLD 4101
T: 07 3069 7457
E: Emily.Milburn@health.qld.gov.au
W: www.childrens.health.qld.gov.au



Children's Health Queensland

Respect | Integrity | Care | Imagination

*Children's Health Queensland acknowledges the Traditional Custodians of the land, and pays respect to Elders past, present and future.
Please consider the environment before printing this email.*

RTI Release

From: [Gregory Perry](#)
To: [Emily Milburn](#)
Subject: Accepted: Neurodevelopmental Disorders Steering Committee Meeting

RTI Release

From: [Gregory Perry](#)
To: "[Oliver Knott](#)"; "[Mark Paternoster](#)"
Subject: RE: QLD weather
Date: Monday, 3 April 2017 1:20:00 PM

Apologies for the delay getting back to you both, I was away on Thursday and Friday last week – but all is ok here with regard to supplies, they go through link and are then stored at our central pharmacy in safe part of Brisbane – not subject to flood

But yes it has certainly been a mighty flood this time.

I note you have now changed back from daylight saving – look forward to catching up on Wednesday 5 April

Kind regards
Greg

From: Oliver Knott [mailto:[\[redacted\]](#)@gwpharm.com]
Sent: Friday, 31 March 2017 12:56 AM
To: Mark Paternoster; Gregory Perry
Subject: RE: QLD weather

Hi Mark,

Shipments are going via link to the central pharmacy in Brisbane, but yes Greg and the team will decide on when the shipments are made so we can work with them to make sure we avoid shipping during situations like this.

Kind regards,

Oliver

From: Mark Paternoster
Sent: 30 March 2017 15:35
To: Oliver Knott; Gregory Perry
Subject: RE: QLD weather

Thanks Oliver. Remind me – shipments to Brisbane are direct, or via Link? If Link, I assume the hospital will make the choice when to request shipment, based on the local transport situation – local government is requesting people to keep off the roads.

Best regards,
Mark

From: Oliver Knott
Sent: 30 March 2017 15:00
To: Gregory Perry
Cc: Mark Paternoster
Subject: RE: QLD weather

Hi Greg,

I hope everybody is safe and well also.

No shipments were in transit from us so no issues from our side. Although we are due to send the next quarterly shipment around now; Greg we can discuss supply levels on the call next week.

Thanks,

Oliver

Oliver Knott | Clinical Project Manager

[Redacted]



Sovereign House, Vision Park, Chivers Way, Histon, Cambridge CB24 9BZ, UK | Tel: [Redacted]
www.gwpharm.com

From: Mark Paternoster
Sent: 30 March 2017 14:39
To: Gregory Perry; Oliver Knott
Subject: QLD weather

Hi Greg

I have been seeing the weather reports for Queensland. I hope you're all safe, and property etc not too badly affected.

Oliver,

Please check the supply chain situation - anything held up?

Best regards
Mark

Mark Paternoster
Epilepsy Portfolio Director

Sent from my BlackBerry 10 smartphone.

PLEASE READ: This email is confidential and may be privileged. It is intended for the named addressee(s) only and access to it by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this email or any action taken (or

not taken) in reliance on it is unauthorised and may be unlawful. If you have received this email in error, please notify the sender or postmaster@gwpharm.com Email is not a secure method of communication and the Company cannot accept responsibility for the accuracy or completeness of this message or any attachment(s). Please check this email for virus infection for which the Company accepts no responsibility. If verification of this email is sought then please request a hard copy. Unless otherwise stated, any views or opinions presented are solely those of the author and do not represent those of the Company.

RTI Release

From: [Gregory Perry](#)
To: [Dorothy Vicenzino](#)
Subject: FW: Neurodevelopmental Disorders Steering Committee: possible CAS protocol change
Date: Monday, 27 March 2017 8:31:00 AM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
Importance: High

FYI

From: Michael Carroll
Sent: Monday, 27 March 2017 8:28 AM
To: Geoff Wallace; Robyn Littlewood; Gregory Perry; Honey Heussler; Melissa Fox; Andrew Hallahan; CHQ_EDMS; Rochelle Green; Helen Irving; Sonya Stacey; Stephen Greene
Cc: Emily Milburn
Subject: FW: Neurodevelopmental Disorders Steering Committee: possible CAS protocol change
Importance: High

Dear Steering Committee members,

Further to my email last Friday regarding the CAS protocol change, please see both Greg's email from earlier this morning and the below email stream. Apologies for the omission and any confusion.

Cheers,

Michael

From: Oliver Knott [mailto:[\[REDACTED\]@gwpharm.com](#)]
Sent: Wednesday, 8 March 2017 1:39 AM
To: Gregory Perry
Subject: RE: GW CBDV Rett Phase II synopsis

Hi Greg,

I have discussed this internally and we believe that as this is a CAS you will be able to make this decision. So it will be up to Geoff to decide if the patients can be included.

Would you update your protocol to allow this?

Kind regards,

Oliver

From: Gregory Perry [mailto:Gregory.Perry@health.qld.gov.au]
Sent: 07 March 2017 00:02

To: Oliver Knott
Subject: RE: GW CBDV Rett Phase II synopsis

Thank you Oliver I will discuss with Honey – it will assist with study design.

When Geoffrey was here, Dr Young discussed with him the possibility of waiving the 1 month cannabis free prior to initiation on Epidiolex

Dr Guy suggested it may be possible in these 2 unique cases but he would need to discuss with the GW team

Could you explore this with the team?

I will further detail the issues when we meet tomorrow

Regards greg

From: Michael Carroll
Sent: Friday, 24 March 2017 3:13 PM
To: Geoff Wallace; Robyn Littlewood; Gregory Perry; Honey Heussler; Melissa Fox; Andrew Hallahan; CHO_EDMS; Rochelle Green; Helen Irving; Sonya Stacey; Michael Carroll; Stephen Greene
Subject: Neurodevelopmental Disorders Steering Committee: possible CAS protocol change
Importance: High

Dear Steering Committee members,

This week's Neurodevelopmental Disorders Steering Committee meeting included a discussion about a possible significant change to the CAS protocol. Given that a number of members were not present, and that our next meeting is a month away, we thought it best to email the topic to all members for consideration and input.

The possible change to the protocol is that the 4-week wait/"wash out" phase that participants must experience before receiving Epidiolex be removed, i.e. essentially allowing participants to receive Epidiolex much sooner after screening and initial data collection. As I understand, the proposed change has originated from Department of Health and Government concerns about the rate at which CAS participants are reaching the point of receiving Epidiolex, i.e. that it is unfavourably slow. GW Pharmaceuticals have been contacted by the Department of Health regarding the change and have replied that they would be ok with it.

Points both for and against the change were discussed at this week's Steering Committee meeting and included:

- The original reason for the 4-week phase was to have a specified period of time before receiving Epidiolex across which other cannabis-related products/medicines would not be taken. This would provide time for products within participants' systems to leave, better allowing examination of Epidiolex as a sole product.
- All CAS applicants have been advised of the 4-week phase; there have been participants fully through it; there are other participants currently within it
- The CAS is a compassionate access scheme and not a trial
- Participants are not tested for cannabis products in their systems at any time during the 4-week phase or remaining scheme
- The CAS protocol has already been revised and approved a number of times,

Can I ask that you please consider the suggested change and send your thoughts to either myself or all Committee members? Please also feel free to correct or amend my account above.

Based on what is sent **by close of business next Wednesday, March 29**, we will determine next steps, including the option of convening a brief meeting with Committee members.

Kind regards,

Michael Carroll

Clinical Research Manager (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service

Level 6 – Centre for Children's Health Research

Lady Cilento Children's Hospital

62 Graham Street, South Brisbane QLD 4101

T: 07 3069 7405 M:

E: Michael.Carroll@health.qld.gov.au

W: www.childrens.health.qld.gov.au



Children's Health Queensland

Service | Integrity | Courage | Innovation | Accountability

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

RTI RELEASED

From: [Gregory Perry](#)
To: [Michael Carroll](#); [Andrew Hallahan](#)
Cc: [Dorothy Vicenzino](#)
Subject: CAS protocol change
Date: Monday, 27 March 2017 7:52:00 AM

Hi Michael, email below received back from Oliver re this matter

Could you circulate to the committee – apologies for the delay getting this to you – I was away on Friday

Regards greg

From: Oliver Knott [redacted]@gwpharm.com]
Sent: Wednesday, 8 March 2017 1:39 AM
To: Gregory Perry
Subject: RE: GW CBDV Rett Phase II synopsis

Hi Greg,

I have discussed this internally and we believe that as this is a CAS you will be able to make this decision. So it will be up to Geoff to decide if the patients can be included.

Would you update your protocol to allow this?

Kind regards,

Oliver

From: Gregory Perry [<mailto:Gregory.Perry@health.qld.gov.au>]
Sent: 07 March 2017 00:02
To: Oliver Knott
Subject: RE: GW CBDV Rett Phase II synopsis

Thank you Oliver I will discuss with Honey – it will assist with study design.

When Geoffrey was here, Dr Young discussed with him the possibility of waiving the 1 month cannabis free prior to initiation on Epidiolex

Dr Guy suggested it may be possible in these 2 unique cases but he would need to discuss with the GW team

Could you explore this with the team?

I will further detail the issues when we meet tomorrow

Regards greg

From: Gregory Perry
To: Dorothy Vicenzino
Subject: Fwd: Neurodevelopmental Disorders Steering Committee: possible CAS protocol change
Date: Monday, 27 March 2017 6:45:27 AM

Discussion thread about removing the one month waiting period

Greg

Sent from my iPhone

Begin forwarded message:

From: Helen Irving <Helen.Irving@health.qld.gov.au>
Date: 25 March 2017 at 3:08:03 pm AEST
To: Stephen Greene <Stephen.Greene@health.qld.gov.au>, Andrew Hallahan <Andrew.Hallahan@health.qld.gov.au>
Cc: Michael Carroll <Michael.Carroll@health.qld.gov.au>, Geoff Wallace <Geoff.Wallace@health.qld.gov.au>, Robyn Littlewood <Robyn.Littlewood@health.qld.gov.au>, Gregory Perry <Gregory.Perry@health.qld.gov.au>, Honey Heussler <H.Heussler@health.qld.gov.au>, Melissa Fox <[REDACTED]@hcq.org.au>, CHQ_EDMS <CHQ_EDMS@health.qld.gov.au>, Rochelle Green <Rochelle.Green@health.qld.gov.au>, Sonya Stacey <Sonya.Stacey@health.qld.gov.au>, Lee Lawrence <Lee.Lawrence@health.qld.gov.au>
Subject: Re: Neurodevelopmental Disorders Steering Committee: possible CAS protocol change

My apologies Stephen and Andrew but I will be away next week at the COG meeting in St Louis.
Kind regards
Helen

Sent from Email+ secured by MobileIron

----- Original Message -----

From: Stephen Greene <Stephen.Greene@health.qld.gov.au>
Date: Sat, 25 Mar 2017, 11:42 AM
To: Andrew Hallahan <Andrew.Hallahan@health.qld.gov.au>
CC: Helen Irving <Helen.Irving@health.qld.gov.au>, Michael Carroll <Michael.Carroll@health.qld.gov.au>, Geoff Wallace <Geoff.Wallace@health.qld.gov.au>, Robyn Littlewood <Robyn.Littlewood@health.qld.gov.au>, Gregory Perry <Gregory.Perry@health.qld.gov.au>, Honey Heussler <H.Heussler@health.qld.gov.au>, Melissa Fox <[REDACTED]@hcq.org.au>, CHQ_EDMS <CHQ_EDMS@health.qld.gov.au>, Rochelle Green <Rochelle.Green@health.qld.gov.au>, Sonya Stacey <Sonya.Stacey@health.qld.gov.au>, Lee Lawrence <Lee.Lawrence@health.qld.gov.au>
Subject: Re: Neurodevelopmental Disorders Steering Committee: possible

CAS protocol change

Andrew and all others.

I agree that we should meet. Opinions were raised at the Steering Committee but it would be good to discuss them again and come to a collective view.

Michael and I are visiting Greg and Dorothy this coming Wednesday, more around the development of a Centre but we will bring back information relevant to this issue.

I will ask Lee to convene a meeting at the end of this week - Thursday or Friday. Appreciate such short notice maybe difficult for all but we should be able to get a consensus.

Steve

Sent from my iPhone

On 25 Mar 2017, at 06:47, Andrew Hallahan
<Andrew.Hallahan@health.qld.gov.au> wrote:

Thanks Helen

Can I request that we convene a brief meeting/teleconference to discuss? There are nuances here that cannot be dealt with by email.

Kind regards

Andrew

Dr Andrew Hallahan

Executive Director Medical Services

Children's Health Queensland Hospital and Health Service

Level 7 Executive Suite

Lady Cilento Children's Hospital, 501 Stanley Street South Brisbane QLD 4101

T: 07 3068 5323 M:

E: Andrew.Hallahan@health.qld.gov.au

W: www.childrens.health.qld.gov.au

<image001.gif><image002.gif><image003.gif><image004.gif><image005.gif>
<image006.gif>

Children's Health Queensland acknowledges the Traditional Custodians of the land, and pays respect to Elders past, present and future.

From: Helen Irving
Sent: Friday, 24 March 2017 6:28 PM
To: Andrew Hallahan; Michael Carroll
Cc: Geoff Wallace; Robyn Littlewood; Gregory Perry; Honey Heussler; Melissa Fox; CHQ_EDMS; Rochelle Green; Sonya Stacey; Stephen Greene
Subject: RE: Neurodevelopmental Disorders Steering Committee: possible CAS protocol change

Thanks Michael

I think your summary is quite reflective.

My concern is that even though this is a Compassionate Access scheme and not a research protocol, there have been a number of changes already to the protocol. The 4 week washout period has been conveyed well to potential patients and they are aware of this.

In terms of recruitment, hopefully the fact that 1/3 of the eligible patients have been discussed, and 2 have commenced on study drug this may reinforce to QH that the study is progressing well. One of the main reasons for ineligibility is not the washout period, but the fact that families are managing their children well at home and as a consequence many have not required hospitalisation in the last 12-18 months.

So I think the protocol should stay as is, that is 2-18 years and with a 4 week washout period.

Best wishes

Helen

From: Andrew Hallahan
Sent: Friday, 24 March 2017 3:24 PM
To: Michael Carroll
Cc: Geoff Wallace; Robyn Littlewood; Gregory Perry; Honey Heussler; Melissa Fox; CHQ_EDMS; Rochelle Green; Helen Irving; Sonya Stacey; Stephen Greene
Subject: Re: Neurodevelopmental Disorders Steering Committee: possible CAS protocol change

Thanks Michael

I was aware of this, have considered and support this change

Kind regards

Andrew

Dr Andrew Hallahan

Executive Director Medical Services

Children's Health Queensland Hospital and Health Service

Level 7 Executive Suite

Lady Cilento Children's Hospital, 501 Stanley Street South Brisbane QLD 4101

T: 07 3068 5323 M:

E: Andrew.Hallahan@health.qld.gov.au

W: www.childrens.health.qld.gov.au



cid:image007.gif@01D1FC85.A56080B0



*Children's Health Queensland acknowledges the Traditional Custodians of the land,
and pays respect to Elders past, present and future.*

On 24 Mar. 2017, at 3:12 pm, Michael Carroll
<Michael.Carroll@health.qld.gov.au> wrote:

Dear Steering Committee members,

This week's Neurodevelopmental Disorders Steering Committee meeting included a discussion about a possible significant change to the CAS protocol. Given that a number of members were not present, and that our next meeting is a month away, we thought it best to email the topic to all members for consideration and input.

The possible change to the protocol is that the 4-week wait/"wash out" phase that participants must experience before receiving Epidiolex be removed, i.e. essentially allowing participants to receive Epidiolex much sooner after screening and initial data collection. As I understand, the proposed change has originated from Department of Health and Government concerns about the rate at which CAS participants are reaching the point of receiving Epidiolex, i.e. that it is unfavourably slow. GW Pharmaceuticals have been contacted by the Department of Health regarding the change and have replied that they would be ok with it.

Points both for and against the change were discussed at this week's Steering Committee meeting and included:

<!--[if !supportLists]-->• <!--[endif]-->The original

reason for the 4-week phase was to have a specified period of time before receiving Epidiolex across which other cannabis-related products/medicines would not be taken. This would provide time for products within participants' systems to leave, better allowing examination of Epidiolex as a sole product.

<!--[if !supportLists]-->• <!--[endif]-->All CAS applicants have been advised of the 4-week phase; there have been participants fully through it; there are other participants currently within it

<!--[if !supportLists]-->• <!--[endif]-->The CAS is a compassionate access scheme and not a trial

<!--[if !supportLists]-->• <!--[endif]-->Participants are not tested for cannabis products in their systems at any time during the 4-week phase or remaining scheme

<!--[if !supportLists]-->• <!--[endif]-->The CAS protocol has already been revised and approved a number of times,

Can I ask that you please consider the suggested change and send your thoughts to either myself or all Committee members? Please also feel free to correct or amend my account above.

Based on what is sent **by close of business next Wednesday, March 29**, we will determine next steps, including the option of convening a brief meeting with Committee members.

Kind regards,

Michael Carroll
Clinical Research Manager (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service
Level 6 – Centre for Children's Health Research
Lady Cilento Children's Hospital
62 Graham Street, South Brisbane QLD 4101

T: 07 3069 7405 M: [REDACTED]

E: Michael.Carroll@health.qld.gov.au

W: www.childrens.health.qld.gov.au

<image001.png><image002.png><image003.png>

<image004.png>

<image005.png>

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

From: [Gregory Perry](#)
To: [Michael Carroll](#)
Cc: [Geoff Wallace](#); [Robyn Littlewood](#); [Honey Heussler](#); [Melissa Fox](#); [Andrew Hallahan](#); [CHO EDMS](#); [Rochelle Green](#); [Helen Irving](#); [Sonya Stacey](#); [Stephen Greene](#)
Subject: Re: Neurodevelopmental Disorders Steering Committee: possible CAS protocol change
Date: Monday, 27 March 2017 6:43:14 AM

Dear all

Just to clarify the reason for the request to GW stemmed from the fact that there are a number of patients that may benefit from compassionate access that currently are giving their children cannabis products and advise that they will not risk stopping treatment for one month to enable entry to the CAS.

They would need to meet all other criteria like all patients but it means they could be considered for the CAS

Regards Greg

Sent from my iPhone

On 24 Mar. 2017, at 3:12 pm, Michael Carroll <Michael.Carroll@health.qld.gov.au> wrote:

Dear Steering Committee members,

This week's Neurodevelopmental Disorders Steering Committee meeting included a discussion about a possible significant change to the CAS protocol. Given that a number of members were not present, and that our next meeting is a month away, we thought it best to email the topic to all members for consideration and input.

The possible change to the protocol is that the 4-week wait/"wash out" phase that participants must experience before receiving Epidiolex be removed, i.e. essentially allowing participants to receive Epidiolex much sooner after screening and initial data collection. As I understand, the proposed change has originated from Department of Health and Government concerns about the rate at which CAS participants are reaching the point of receiving Epidiolex, i.e. that it is unfavourably slow. GW Pharmaceuticals have been contacted by the Department of Health regarding the change and have replied that they would be ok with it.

Points both for and against the change were discussed at this week's Steering Committee meeting and included:

- <!--[if !supportLists]-->• <!--[endif]-->The original reason for the 4-week phase was to have a specified period of time before receiving Epidiolex across which other cannabis-related products/medicines would not be taken. This would provide time for products within participants' systems to leave, better allowing examination of Epidiolex as a sole product.
- <!--[if !supportLists]-->• <!--[endif]-->All CAS applicants have been advised of the 4-week phase; there have been participants fully through it; there are other participants currently within it
- <!--[if !supportLists]-->• <!--[endif]-->The CAS is a compassionate access scheme and not a trial

<!--[if !supportLists]-->• <!--[endif]-->Participants are not tested for cannabis products in their systems at any time during the 4-week phase or remaining scheme

<!--[if !supportLists]-->• <!--[endif]-->The CAS protocol has already been revised and approved a number of times,

Can I ask that you please consider the suggested change and send your thoughts to either myself or all Committee members? Please also feel free to correct or amend my account above.

Based on what is sent **by close of business next Wednesday, March 29**, we will determine next steps, including the option of convening a brief meeting with Committee members.

Kind regards,

Michael Carroll

Clinical Research Manager (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service

Level 6 – Centre for Children's Health Research

Lady Cilento Children's Hospital

62 Graham Street, South Brisbane QLD 4101

T: 07 3069 7405 M:

E: Michael.Carroll@health.qld.gov.au

W: www.childrens.health.qld.gov.au

<image001.png><image002.png><image003.png><image004.png>

<image005.png>

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

RTI Release

From: [Gregory Perry](#)
To: [Andrew Hallahan](#)
Cc: [Dorothy Vicenzino](#); [Stephen Greene](#); [Honey Heussler](#)
Subject: Re: Advice requested re CHQ Research plan
Date: Tuesday, 21 March 2017 6:18:52 AM

Thanks Andrew

Greg

Sent from my iPhone

On 20 Mar. 2017, at 6:39 pm, Andrew Hallahan <Andrew.Hallahan@health.qld.gov.au> wrote:

Hi Dorothy and Greg

A CHQ Research Plan has been developed for medicinal cannabinoids in children with neuro-developmental/neurologic disorders.

The CHQ Chief Executive is reviewing this

Once endorsed can you please advise re submission?

Thank you

Andrew

Dr Andrew Hallahan
Executive Director Medical Services

Children's Health Queensland Hospital and Health Service
Level 7 Executive Suite
Lady Cilento Children's Hospital, 501 Stanley Street South Brisbane QLD 4101

T: 07 3068 5323 M:
E: Andrew.Hallahan@health.qld.gov.au
W: www.childrens.health.qld.gov.au

<image001.gif> <image002.gif> <image003.gif> <image004.gif> <image005.gif>
<image006.gif>

Children's Health Queensland acknowledges the Traditional Custodians of the land, and pays respect to Elders past, present and future.

From: [Gregory Perry](#)
To: [Dorothy Vicenzino](#)
Cc: [Andrew Hallahan](#); [Geoff Wallace](#); [Honey Heussler](#); [Stephen Greene](#); [CHO EDMS](#)
Subject: Re: Follow up on CHQ medicinal cannabis plans
Date: Wednesday, 15 March 2017 7:14:27 AM

Thanks Andrew, we have the symposium next Thursday 23 march- if all ok, this may be something that Geoff and honey include in that forum?

Greg

Sent from my iPhone

On 14 Mar. 2017, at 9:42 pm, Dorothy Vicenzino
<Dorothy.Vicenzino@health.qld.gov.au> wrote:

Thank you

Sent from my iPhone

On 14 Mar. 2017, at 8:41 pm, Andrew Hallahan
<Andrew.Hallahan@health.qld.gov.au> wrote:

Hi Dorothy and Greg
Thank you for meeting last week
This is to advise you that a CHO medicinal cannabis research plan that will meet the requirements of the MOU has been drafted and will be submitted to you and Jeannette early next week.
Kind regards
Andrew

Dr Andrew Hallahan
Executive Director Medical Services

Children's Health Queensland Hospital and Health Service
Level 7 Executive Suite
Lady Cilento Children's Hospital, 501 Stanley Street
South Brisbane QLD 4101

W: [0730681000](tel:0730681000) M: [0730681000](tel:0730681000) U:
E: Andrew.Hallahan@health.qld.gov.au



*Children's Health Queensland acknowledges the Traditional Custodians of the land,
and pays respect to Elders past, present and future.*

RTI Release

From: [Gregory Perry](#)
To: [MCTeam](#)
Subject: Re: Authorised Prescriber - Paperwork for Honey Heussler to Complete
Date: Tuesday, 14 March 2017 9:18:46 AM

Yes please!

Sent from my iPhone

> On 14 Mar. 2017, at 8:54 am, MCTeam <MCTeam@health.qld.gov.au> wrote:
>
> Hi Greg
>
> Did you want me to start the DG Brief for Approval for this one under PHMCA?
>
> Tanya
>
> From: Emily Milburn
> Sent: Monday, 13 March 2017 3:19 PM
> To: MCTeam
> Cc: Susan Ballantyne; Honey Heussler
> Subject: RE: Authorised Prescriber - Paperwork for Honey Heussler to Complete
> Importance: High
>
> Thanks Tanya!
>
> Please see attached completed application form and supporting ethics endorsement letters.
>
> If you need anything further, please don't hesitate to let me know.
>
> Kind regards
> Emily
> Emily Milburn
> Administration Officer (Neurodevelopmental Disorders)
> Department of Neurology
> Children's Health Queensland Hospital and Health Service
> Level 6 – Centre for Children's Health Research
> Lady Cilento Children's Hospital Precinct
> 62 Graham Street, South Brisbane QLD 4101
> T: 07 3069 7457
> E: Emily.Milburn@health.qld.gov.au <<mailto:Emily.Milburn@health.qld.gov.au>>
> W: www.childrens.health.qld.gov.au <<http://www.childrens.health.qld.gov.au>>
> [cid:image006.gif@01D29C0D.319FCD70]
>
> [cid:image007.gif@01D29C0D.319FCD70]
>
>
> Children's Health Queensland acknowledges the Traditional Custodians of the land,
> and pays respect to Elders past, present and future.
> Please consider the environment before printing this email.
>
>
>
>
> From: MCTeam
> Sent: Monday, 13 March 2017 2:52 PM
> To: Emily Milburn
> Cc: Susan Ballantyne

> Subject: Authorised Prescriber - Paperwork for Honey Heussler to Complete
>
> Good afternoon Emily
>
> Dr Susan Ballantyne, Senior Medical Advisor, Chief Medical Officer and Healthcare Regulation Branch has requested that I forward a copy of the 'Application for Medicinal Cannabis Clinical Trial Approval' for Dr Heussler to complete in regards to prescribing the medical cannabis product.
>
> Please see electronic form attached.
>
> Should you have any queries please do not hesitate to contact the Medicinal Cannabis Team
>
>
> Kind regards
>
>
> [cid:image008.gif@01D29C0D.319FCD70]
>
> Tanya Bain
>
> Principal Policy Officer
>
> Medicinal Cannabis Team | Chief Medical Officer and Healthcare Regulation Branch, Department of Health
>
> p:
>
> 07 3328 9817
>
> a:
>
> Level 3 15 Butterfield Street Herston Qld 4006
>
> w:
>
> Queensland Health<<https://www.health.qld.gov.au/>> | e:
> Tanya.Bain@health.qld.gov.au<<mailto:Tanya.Bain@health.qld.gov.au>>
>
> [cid:image009.jpg@01D29C0D.319FCD70]<<http://www.facebook.com/qlhealth>>
> [cid:image010.jpg@01D29C0D.319FCD70] <<http://www.linkedin.com/company/queensland-health>>
> [cid:image011.jpg@01D29C0D.319FCD70] <<http://www.twitter.com/qlhealthnews>>
> [cid:image012.jpg@01D29C0D.319FCD70]
> <https://www.youtube.com/channel/UCN_P6BgIO9MHFzktKgJzYFw>
>
>
>
>
> Queensland's health vision | By 2026 Queenslanders will be among the healthiest people in the world.<<https://www.health.qld.gov.au/publications/portal/health-strategies/vision-strat-healthy-qld.pdf>>
>
>
> Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.
>
>
>
>
> <Heussler, Honey_MC_Application_ClinicalTrials_Completed.pdf>
> <Letter of Endorsement - Heussler - 020217.pdf>
> <HREC16QRCH384 - HREC Approval Letter.pdf>
> <image006.gif>
> <image007.gif>

RELEASE

- > <image008.gif>
- > <image009.jpg>
- > <image010.jpg>
- > <image011.jpg>
- > <image012.jpg>

RTI Release